CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Income Statement [Abstract]
Product royalty revenues	$ 953,990
Research and development reimbursements	8,451,979
Contract revenues	11,283,833	1,621,977
Total revenues:	20,689,802	1,621,977
Cost of product royalty revenues	725,597	375,000
Expenses:
Research and development	14,623,221	12,032,168
General and administrative	4,622,024	2,910,256
Related party general and administrative	6,000	16,500
Total expenses:	19,251,245	14,958,924
Income (loss) from operations	712,960	(13,711,947)
Interest (expense) income, net	(555,245)	72,510
Derivative (loss) gain	(4,825,458)	1,024,951
Other income (expense), net	23,332	(23,154)
Loss before taxes	(4,644,411)	(12,637,640)
Income tax expense		(85,000)
Net loss attributable to common stockholders	$ (4,644,411)	$ (12,722,640)
Basic and diluted loss per share	$ (0.11)	$ (0.34)
Weighted average common stock shares outstanding	44,035,288	37,511,326